← Back to Search

Virus Therapy

HIV Vaccine for Human Immunodeficiency Virus Infection

Q: Are there any known risks associated with the BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted?

<p>The safety of the BG505 SOSIP GT1.1 gp140 <a href="https://www.withpower.com/clinical-trials/vaccine">Vaccine</a>, Adjuvanted has been evaluated by our team at Power and given a score of 1 due to limited clinical data supporting its efficacy and safety in this Phase 1 trial.</p>

Phase 1

Waitlist Available

Led By Marina Caskey, MD

Research Sponsored by International AIDS Vaccine Initiative

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 18 months

Awards & highlights

Study Summary

This trial is testing a new HIV vaccine to see if it is safe and causes an immune response.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety - Grade 2 or greater unsolicited AEs

Safety - IP related SAEs

Safety - IP related unsolicited adverse events

+2 more

Secondary outcome measures

Immunogenicity - Frequency Ab responses

Immunogenicity - Magnitude Ab responses

Trial Design

2Treatment groups

Experimental Treatment

Group I: Investigational Product, 300 µg/ PlaceboExperimental Treatment2 Interventions

300 µg IM, months 0, 2 and 6

Group II: Investigational Product, 30 µg/ PlaceboExperimental Treatment2 Interventions

30 µg IM, months 0, 2 and 6

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Placebo

1995

Completed Phase 3

~2670

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

International AIDS Vaccine InitiativeLead Sponsor

48 Previous Clinical Trials

13,212 Total Patients Enrolled

George Washington UniversityOTHER

243 Previous Clinical Trials

453,726 Total Patients Enrolled

Rockefeller UniversityOTHER

158 Previous Clinical Trials

16,309 Total Patients Enrolled

Media Library

BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04224701 — Phase 1

Human Immunodeficiency Virus Infection Research Study Groups: Investigational Product, 300 µg/ Placebo, Investigational Product, 30 µg/ Placebo

Human Immunodeficiency Virus Infection Clinical Trial 2023: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted Highlights & Side Effects. Trial Name: NCT04224701 — Phase 1

BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04224701 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there opportunities for volunteers to participate in this research endeavor?

"Clinicaltrials.gov has noted that while this trial, initially posted on August 1st 2020 and updated as recently as May 6th 2022, is no longer recruiting patients; there are 484 other trials actively looking for participants at the moment."

Answered by AI

To whom is this study open for participation?

"In order to be considered for this study, participants ought to have HIV and lie within the age range of 18-51. Currently, 48 applicants are being sought after by the clinical trial team."

Answered by AI

Does the age cutoff for this trial extend beyond eighty-five years of age?

"The age range for enrollment in this medical trial is 18 to 51 years old."

Answered by AI

Are there any known risks associated with the BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted?

"The safety of the BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted has been evaluated by our team at Power and given a score of 1 due to limited clinical data supporting its efficacy and safety in this Phase 1 trial."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

2020. "A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04224701.